Mobile

A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer. E...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001921-25

A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Ensayo clínico fase II, abierto, aleatorizado con tres brazos de tratamiento de 2 esquemas de la combinación de ixabepilona y bevacizumab frente a la de paclitaxel y bevacizumab como primera línea de tratamiento del cáncer de mama tras recaída local o metastásica Revised Protocol 01, Incorporating Protocol Amendment 01 (Version 1.0, Date 07-Dec-2006). And Pharmacogenetics Blood Sample Amendment 02 - Site Specific (Version 2.0, Date 12-Dec-2006)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate the response rate of ixabepilone/bevacizumab combination in each of the following 2 schedules relative to the reference arm of paclitaxel plus bevacizumab: • Ixabepilone administered every week for 3 weeks followed by 1 week rest plus bevacizumab administered every 2 weeks (Arm A) and • Ixabepilone administered every 3 weeks plus bevacizumab administered every 3 weeks (Arm B).

Critère d'inclusion

  • Locally Recurrent or Metastatic Breast Cancer,Cáncer de mama localmente recidivante o metastásico

Liens